Galvani Bioelectronics

Executive Summary

Galvani Bioelectronics is a UK-based pioneer in bioelectronic medicine, developing implantable neuromodulation devices that treat chronic diseases by modulating neural signals to specific organs. Founded in 2016, the company’s lead program targets the splenic nerve to modulate the immune system for the treatment of Rheumatoid Arthritis (RA). This approach offers a potential alternative or adjunct to biologic drugs, aiming to reduce inflammation via electrical stimulation rather than systemic pharmaceuticals. Galvani’s technology leverages decades of research in neural-immune interactions and represents a paradigm shift in treating autoimmune conditions. The company operates in the emerging field of bioelectronic therapeutics, which faces significant technical and regulatory hurdles, including precise targeting, implant durability, and long-term safety data. Galvani’s platform could extend beyond RA to other inflammatory diseases if successful. While still preclinical or early clinical, the company benefits from a strong intellectual property position and collaborations with academic and industry partners. Near-term success hinges on clinical proof-of-concept data and securing additional financing. With the growing interest in neuromodulation and digital health, Galvani is well-positioned to be a leader in this space, though execution risk remains high.

Upcoming Catalysts (preview)

• Q2 2026Phase 1/2 Clinical Trial Results for Rheumatoid Arthritis40% success
• Q4 2026FDA IDE Approval for US Clinical Study55% success
• H2 2026Strategic Partnership or Licensing Deal with Major Pharma30% success